Thursday 23 May 2019

08:30-08:40  
Welcome  
Introduction and Acknowledgements  
Associate Professor Antiopi Varelias

08:40-08:50  
Welcome and Conference Objectives  
Professor David Whiteman

08:50-09:00  
Welcome to Brisbane  
Hon Dr Steven Miles, the Minister for Health and Minister for Ambulance Services in the Palaszczuk Labor Government

Session I: Keynote Lecture  
Chair: Professor Ranjeny Thomas

09:00-10:00  
Professor Marco Colonna, Department of Pathology and Immunology, Washington University, St. Louis

10:00-10:30  
Morning tea

Session II: Immunotherapy for autoimmune diseases  
Chair: Professor Ranjeny Thomas

10:30-11:00  
Professor Qizhi Tang, Director, UCSF Transplantation Research Lab, Department of Surgery, University of California, San Francisco  
Translating regulatory T cell therapy to the clinic

11:00-11:20  
Dr Emma Hamilton-Williams, The University of Queensland Diamantina Institute  
Antigen-specific immunotherapy for type 1 diabetes

11:20-11:35  
Dr Anne-Sophie Bergot, The University of Queensland Diamantina Institute  
Regulatory T cells induced following single antigen immunotherapy suppress islet-specific T cell responses to multiple antigens and protect from autoimmune diabetes

11:35-11:50  
Pascale Wehr, The University of Queensland Diamantina Institute  
Arthritogenic clonally-expanded autoantigen-specific CD4+ T cells are a target for prevention of autoimmune arthritis

11:50-12:05  
Aimee Hanson, The University of Queensland Diamantina Institute  
T-cell receptor immunosequencing reveals disease-associated clonal expansions and altered repertoire diversity in ankylosing spondylitis patients

12:05-13:15  
Lunch
Session III: Immunotherapy and the tumour microenvironment
Chair: Dr Tobias Bald

13:15-13:45  Professor Matthew Krummel. Department of Pathology, University of California San Francisco (UCSF)
Disseminating Tumor-Self via A Synaptic Cellular ‘Mancala’

13:45-14:05  Associate Professor Thomas Gebhardt. Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity
Tissue-resident memory T cells promote melanoma-immune equilibrium in skin

14:05-14:20  Dr Ailin Lepletier. QIMR Berghofer Medical Research Institute
Tumor-intrinsic CD155 expression limits sensitivity to anti-PD-1 therapy in advanced metastatic melanoma

14:20-14:35  Diana Canals-Hernaez. The Biomedical Research Centre, University of British Columbia, Canada
Podocalyxin is a therapeutic target in carcinoma

14:35-14:50  Alvaro Sanchez-Herrero. Institute of Health & Biomedical Innovation, Queensland University of Technology
Tissue engineering of an orthotopic humanised bone-organ as a platform for preclinical multiple myeloma research

14:50-15:30  Afternoon Tea

Session IV: Adoptive immunotherapies
Chair: Associate Professor Corey Smith and Dr Ashleigh Poh

15:30-16:00  Dr Emily Blyth. Westmead Clinical School, The Westmead Institute for Medical Research and Westmead Hospital - BMT Cell Therapies, Sydney
The way forward for antigen-specific T cells for immune reconstitution – stem cell donors or third party cell banks?

16:00-16:20  Dr Paulo Martins. Tumour Immunology Group, QIMR Berghofer Medical Research Institute
Serotherapy prevents cytomegalovirus reactivation after transplantation

16:20-16:35  Associate Professor Corey Smith. QIMR Berghofer Medical Research Institute
Restructuring of the TRBV landscape is coincident with clinical response to T cell therapy in transplant recipients

16:35-16:50  Simone Minnie. QIMR Berghofer Medical Research Institute
Stem cell transplantation establishes T cell-dependent myeloma immune-equilibrium that can be enhanced with immunotherapy

16:50-17:05  Dr Matthias Braun. QIMR Berghofer Medical Research Institute
Loss of DNAM-1 on CD8+ T cells: a novel immune escape mechanism
17:00-19:00  Poster session I / Welcome Reception

19:00-20:00  Public Forum
Sponsored by Icon Group Australia
For more details and to register, visit the event website

Friday 24 May 2019

Session V: Keynote Lecture
Chair: Professor Mark Smyth

08:30-09:30  Professor Matthew Krummel, Department of Pathology, University of California San Francisco (UCSF)
*Imaging a World Beyond Checkpoint: Archetypes of Immunity in Tumors and Beyond*

Session VI: Adenosine: the new kid on the block
Chair: Associate Professor Michele Teng

09:30-09:50  Associate Professor John Stagg, CRCHUM and Institute of Cancer, University of Montreal
*Targeting CD73 in cancer immunotherapy: beyond adenosine inhibition*

09:50-10:10  Dr Courtney Beers, Vice President, Immunology, Tizona Therapeutics, San Francisco
*Targeting CD39 with a First-in-Class Inhibitory Antibody Prevents ATP Processing and Increases T-Cell Activation*

10:10-10:30  Dr Pam Holland, Vice President, Cancer Biology, Surface Oncology, Cambridge
*Targeting the Adenosine Axis to Treat Cancer*

10:30-11:00  Morning Tea

Session VII: Immunogenomics
Chair: Dr Nic Waddell

11:00-11:30  Dr Jinmiao Chen, Single-Cell Computational Immunology (SCCI), Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore
*Single-cell analysis of crosstalk between tumor, immune cells and pathogens in gastric cancer*
11:30-11:45  
**Dr Ann-Marie Patch**, Head of Clinical Genomics Group, QIMR Berghofer Medical Research Institute  
*Bridging the fields of cancer genomics and immunotherapy*

11:45-12:00  
**Dr Andreas Behren**, Olivia Newton-John Cancer Research Institute  
*The immunopeptidome of melanoma*

12:00-12:15  
**Dr Simon Junankar**, Garvan Institute of Medical Research  
*DNA barcoding demonstrates immuno-editing of metastatic breast cancer cells at the clonal level*

12:15-12:30  
**Dr Jessica Engel**, QIMR Berghofer Medical Research Institute  
*Mapping the Development of Gut Pathogenic CD4+ T-cells during Graft-versus-Host Disease using single-cell RNA-seq*

12:30-13:30  
**Lunch**

13:30-14:00  
**Dr Jan Böttcher**, Institute of Molecular Immunology and Experimental Oncology, Technical University Munich  
*The role of cDC1/NK cell communication within the tumor microenvironment for anti-cancer immunity*

14:00-14:20  
**Dr Tatyana Chtanova**, Innate and Tumour Immunology, Garvan Institute of Medical Research  
*Innate immune cells in cancer: Teaching neutrophils new tricks*

14:20-14:35  
**Juming Yan**, QIMR Berghofer Medical Research Institute  
*TBC*

14:35-14:50  
**Associate Professor Eynav Klechevsky**, Washington University School of Medicine, St. Louis  
*Upstream activation of anti-tumor immunity via human dendritic cell subsets*

14:50-15:05  
**Amanda Oliver**, Peter MacCallum Cancer Centre  
*Tissue-specific differences in the tumour microenvironment and their influence on immunotherapeutic responses*

15:05-15:30  
**Afternoon Tea**

15:30-16:00  
**Dr Beth Helmink**, Department of Surgical Oncology and Genomic Medicine, University of Texas MD Anderson Cancer Centre  
*Bringing concepts to clinic: the gut microbiome and the response to and toxicity of immune checkpoint blockade in melanoma*
Professor Emad El-Omar, Director, Microbiome Research Centre, St George and Sutherland Clinical School, University of New South Wales
The role of the microbiome in GI cancer

Dr Nadeem Kaakoush, Head of Host-Microbiome Interactions Group, School of Medical Sciences, University of New South Wales, Sydney
Microbiome manipulation through faecal microbiota transplantation therapy

Session X: Immunotherapy and infectious diseases
Chair: Dr Janin Chandra

Professor Man-Wah Tan, Infectious Diseases Therapeutic Area, Genentech, San Francisco, California
Harnessing nature’s gift: antibody and antibody-antibiotic conjugates to treat bacterial infections

Dr Keith Chappell, School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland
Rapid response pipeline for stabilized subunit vaccines

Dr Christian Engwerda, QIMR Berghofer Medical Research Institute
Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of malaria and visceral leishmaniasis.

Dr Manisha Pandey, Institute for Glycomics, Griffith University
Immunotherapy with antibodies to the conserved region of the M protein and a streptococcal superantigen cooperatively resolve toxic shock-like syndrome in HLA humanized mice

18:05-19:30 Poster session II / Light Refreshments

Saturday 25 May 2019

Session XI: Plenary Session: Neoadjuvant immunotherapy - a game changer?
Chair: Dr Elizabeth Ahern

Professor Christian Blank, Department of Medical Oncology & Division of Immunology, Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam
Neoadjuvant Immunotherapy – the pathway to personalized immunotherapy in melanoma and beyond

10:00-10:30 Associate Professor Michele Teng, Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute
Neoadjuvant immunotherapy and surgery – a window of opportunity for tumor-specific T cell memory differentiation
10:30-11:00  Morning Tea

**Session XII: CAR-T cells: Beyond blood cancers**

Chair: Dr Siok Tey

11:00-11:30  
**Professor Stephen Gottschalk**, Dept. of Bone Marrow Transplantation & Cellular Therapy, St. Jude Children’s Hospital
*Engineering Lymphocytes for the Adoptive Immunotherapy of Solid Tumors*

11:30-11:50  
**Professor Simon Barry**, Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide
*Targeting nfp2x7 for pan cancer CAR-T therapy? The story so far…*

11:50-12:05  
**Dr Blake Aftab**, Preclinical and Translational Sciences, Atara Biotherapeutics
*CD19 Chimeric Antigen Receptor (CAR) Engineered Epstein-Barr Virus (EBV) Specific T cells – An Off-the-Shelf, Allogeneic CAR T-Cell Immunotherapy Platform*

12:05-12:20  
**Professor Riccardo Dolcetti**, The University of Queensland Diamantina Institute
*Enhancing CAR-T cell immunotherapy against solid tumours by exploiting nanoemulsion-based indirect vaccination*

12:20-12:35  
**Jessica Michie**, Peter MacCallum Cancer Centre
*Antagonism of IAPs enhances CAR T cell efficacy*

12:45-14:00  Lunch

**Session XIII: Clinical immuno-oncology**

Chair: Dr Andrea Henden

14:00-14:20  
**Associate Professor Victoria Atkinson**, School of Clinical Medicine, The University of Queensland and Medical Oncologist, Princess Alexandra and Greenslopes Private Hospitals, Brisbane
*Modern Immunotherapy for advanced melanoma*

14:20-14:40  
**Professor Sandro Porceddu**, Director Radiation Oncology Research, Cancer Services, Princess Alexandra Hospital and Faculty of Medicine, University of Queensland
*The evolution and role of immunotherapy in head and neck cancer*

14:40-15:00  
**Professor Ken O’Byrne**, Medical Oncologist, Princess Alexandra Hospital, Queensland University of Technology, Translational Research Institute

15:00-15:20  
**Dr Alistair Cook**, Research Fellow, Faculty of Health and Medical Sciences, UWA Medical School, The University of Western Australia
*Results of a phase 2 trial of DuRvalumab with first line chemotherapy in Mesothelioma (DREAM)*

15:20-15:50  Award Presentations and Closing Remarks